Philips says no new French probe opened over sleep device recall

Philips announced that France has not initiated a new investigation into its sleep apnea device recall, countering recent media reports that had caused its shares to drop. The company clarified that existing proceedings, launched in 2023, address its activities leading up to and during the 2021 global recall of approximately 15 million devices, including 350,000 in France, and do not concern currently marketed products. This statement, following a $1.1 billion US litigation settlement last year, helped temper a significant share price decline, providing clarity on the scope of its ongoing legal challenges.

Analysis

Philips (PHG.AS) moved to contain legal uncertainty by clarifying that no new criminal probe has been opened in France concerning its 2021 sleep apnea device recall. This statement followed a sharp, nearly 5% drop in its share price on media reports, with the stock later paring losses to trade down 1.3%, underscoring the market's high sensitivity to litigation developments. The company confirmed an existing proceeding, initiated in 2023, is focused on its conduct leading up to and during the recall of 15 million devices worldwide, but specified that it does not pertain to the safety of products currently sold in France. This event serves as a critical reminder of the persistent legal overhang from the recall, which has already resulted in a significant $1.1 billion settlement in the U.S., and indicates that liabilities in other jurisdictions remain a key unquantified risk for the company.

Key Decisions for Investors

• The stock's immediate 5% drop on unconfirmed reports highlights extreme headline risk; investors should anticipate continued volatility tied to any news flow regarding the global recall litigation.
• While the company's clarification provided temporary relief, the ongoing 2023 French proceeding represents a material, unquantified liability that must be monitored closely, especially as the $1.1 billion U.S. settlement sets a significant precedent.
• Consider that Philips is actively trying to separate past liabilities from its current business, but the persistent legal battles from the 2021 recall remain the dominant risk factor and will likely continue to weigh on valuation until fully resolved.